{
    "2021-10-13": [
        [
            {
                "time": "2021-10-22",
                "original_text": "康泰生物：公司目前预约第三季度报告的披露时间为2021年10月22日",
                "features": {
                    "keywords": [
                        "第三季度报告",
                        "披露时间"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-unknown",
                "original_text": "康泰生物：公司已积极安排13价肺炎球菌多糖结合疫苗的生产、销售工作",
                "features": {
                    "keywords": [
                        "13价肺炎球菌多糖结合疫苗",
                        "生产",
                        "销售"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-06-unknown",
                "original_text": "康泰生物：新冠灭活疫苗III期临床试验在今年6月已开始接种首针",
                "features": {
                    "keywords": [
                        "新冠灭活疫苗",
                        "III期临床试验",
                        "接种首针"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-unknown",
                "original_text": "康泰生物：公司生产经营正常，生产基地所在区域不限电措施影响",
                "features": {
                    "keywords": [
                        "生产经营正常",
                        "不限电措施"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-unknown",
                "original_text": "康泰生物：公司民海生物新型疫苗国际化产业基地建设项目（一期）尚处于建设期",
                "features": {
                    "keywords": [
                        "民海生物",
                        "新型疫苗",
                        "国际化产业基地",
                        "建设期"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-unknown",
                "original_text": "康泰生物：公司研发人员占公司总人数的比例在20%左右",
                "features": {
                    "keywords": [
                        "研发人员",
                        "比例",
                        "20%"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}